Incubating Hope for Patients with Rare and Infectious Diseases

As a leader in the infectious disease field, Spero Therapeutics is highly committed to advancing new therapies for patients with rare orphan diseases and serious, multi-drug resistant bacterial infections in both hospital and community settings.

SPR720

Oral antibiotic designed to treat Nontuberculous Mycobacterial Pulmonary disease, a rare disease

SPR720 has potential to be the first approved novel oral agent for nontuberculous mycobacterial (NTM), addressing a significant unmet need to arrest infection and prevent the lung damage that infection causes. If approved, the broad spectrum oral candidate may be applicable to both non-refractory and refractory patients. Once daily dosing is supported by clinical and non-clinical studies.

SPR206

SPR206 is an innovative, investigational intravenous (IV) direct-acting antibiotic that has shown antibiotic activity against multi-drug resistant (MDR) Gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in preclinical studies.

Learn more about SPR206

Tebipenem HBr

Our product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide) is designed as an oral antibiotic for the treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) to help patients avoid hospitalizations and/or transition patients home after IV therapy.

Solutions for NTM disease and MDR bacterial infections


Nontuberculous Mycobacterium (NTM) pulmonary disease is a growing global health concern and a significant unmet medical need, due to a lack of new medications being developed to combat these bacteria. Treatment failure is common for patients with NTM. The absence of effective and well-tolerated drugs leaves patients without options and increasingly desperate for solutions.

Spero is answering the call with an audacious mission to find new answers and new treatment approaches to combat rare diseases and MDR bacterial infections for future generations.

Partnerships

Spero Therapeutics is pursuing collaborations with partners for expertise and funding support.

Careers

Collaborative. Exciting. Challenging. Stimulating. Committed. Find opportunities to join our team.

Investor Relations

Stock information, SEC filings, corporate governance, IR resources and more.

Sign up to receive news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.